DelveInsight’s, “Amyloid Beta-Protein Inhibitors– Pipeline Insight, 2022,” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Amyloid Beta-Protein Inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Amyloid Beta-Protein Inhibitors: Overview
Amyloid-β (Aβ) denotes peptides of 36–43 amino acids that are crucially involved in Alzheimer's disease as the main component of theamyloid plaques found in the brains of Alzheimer patients. The peptides result from the amyloid precursor protein (APP), which is being cut by certain enzymes to yield Aβ. Amyloid-β molecules can aggregate to form flexible soluble oligomers which may exist in several forms. Amyloid-β peptide is due to overproduction of Aβ and/or the failure of clearance mechanisms. Amyloid-β self-aggregates into oligomers, which can be of various sizes, and forms diffuse and neuritic plaques in the parenchyma and blood vessels.
Function – The progressive production and subsequent accumulation of β-amyloid (Aβ), a proteolytic fragment of the membrane-associated amyloid precursor protein (APP), plays a central role in Alzheimer's disease (AD). Aβ is released in a soluble form that may be responsible for cognitive dysfunction in the early stages of the disease, then progressively forms oligomeric, multimeric and fibrillar aggregates, triggering neurodegeneration. Eventually, the aggregation and accumulation of Aβ culminates with the formation of extracellular plaques, one of the morphological hallmarks of the disease, detectable post-mortem in AD brains.
Amyloid Beta-Protein Inhibitors- Inhibition of the formation of these toxic polymers of Aβ has thus emerged as an approach to developing therapeutics for AD. Therefore, blocking the initial stages of Aβ peptide aggregation with small molecules could hold considerable promise as the starting point for the development of new therapies for AD.
This segment of the Amyloid Beta-Protein Inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Amyloid Beta-Protein Inhibitors Emerging Drugs
Aducanumab: Biogen
Biogen’s aducanumab — a monoclonal antibody is currently under review by the U.S. Food and Drug Administration. If ultimately approved, it is predicted that the drug, which only showed modest efficacy in phase III clinical trial, could become the best-selling drug of all time.
Crenezumab: Hoffman-La-Roche
Crenezumab (RG7412) is a humanized monoclonal antibody, which binds to amyloid beta (Abeta). Abeta is the main constituent of amyloid plaque in the brains of patients with Alzheimer's disease and is proposed to be causative in the development of the disease. A phase II clinical trial is evaluating Crenezumab in healthy individuals with a history of familial Alzheimer’s disease. Roche plans to submit regulatory applications for marketing Crenezumab for Alzheimer's disease by 2023.
Further product details are provided in the report……..
This segment of the report provides insights about the different Amyloid Beta-Protein Inhibitors drugs segregated based on following parameters that define the scope of the report, such as:
There are approx. 10+ key companies which are developing the Amyloid Beta-Protein Inhibitors. The companies which have their Amyloid Beta-Protein Inhibitors drug candidates in the most advanced stage, i.e. preregistration include Biogen.
DelveInsight’s report covers around 10+ products under different phases of clinical development like
Amyloid Beta-Protein Inhibitors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Products have been categorized under various Molecule types such as
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Amyloid Beta-Protein Inhibitors therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Amyloid Beta-Protein Inhibitors drugs.
Current Scenario and Emerging Therapies:
Introduction
Executive Summary
Amyloid Beta-Protein Inhibitors: Overview
Pipeline Therapeutics
Therapeutic Assessment
Amyloid Beta-Protein Inhibitors – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Amyloid Beta-Protein Inhibitors Collaboration Deals
Late Stage Products (Preregistration)
Aducanumab: Biogen
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
R-phenserine: Annovis Bio
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
Fol PRI 002: Priavoid
Drug profiles in the detailed report…..
Inactive Products
Amyloid Beta-Protein Inhibitors Key Companies
Amyloid Beta-Protein Inhibitors Key Products
Amyloid Beta-Protein Inhibitors- Unmet Needs
Amyloid Beta-Protein Inhibitors- Market Drivers and Barriers
Amyloid Beta-Protein Inhibitors- Future Perspectives and Conclusion
Amyloid Beta-Protein Inhibitors Analyst Views
Amyloid Beta-Protein Inhibitors Key Companies
Appendix
List of Table
Table 1: Total Products for Amyloid Beta-Protein Inhibitors
Table 2: Late Stage Products
Table 3: Mid Stage Products
Table 4: Early Stage Products
Table 5: Pre-clinical & Discovery Stage Products
Table 6: Assessment by Product Type
Table 7: Assessment by Stage and Product Type
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Molecule Type
Table 11: Assessment by Stage and Molecule Type
Table 12: Inactive Products
List of Figures
Figure 1: Total Products for Amyloid Beta-Protein Inhibitors
Figure 2: Late Stage Products
Figure 3: Mid Stage Products
Figure 4: Early Stage Products
Figure 5: Preclinical and Discovery Stage Products
Figure 6: Assessment by Product Type
Figure 7: Assessment by Stage and Product Type
Figure 8: Assessment by Route of Administration
Figure 9: Assessment by Stage and Route of Administration
Figure 10: Assessment by Molecule Type
Figure 11: Assessment by Stage and Molecule Type
Figure 12: Inactive Products
• Cytos Biotechnology
• Hoffman- La- Roche
• Priavoid
• Eli Lilly and Company
• Annovis Bio
• Affiris
• Eisai
• Biogen
